A 2011 meta-analysis of 2183 patients by Thompson and colleagues found that newly diagnosed, DMARD-naive patients did not have an increased risk of serious infection or malignancy when treated with TNF inhibitors. Similarly, a large-scale, prospective study by Lunt and colleagues of 12,672 patients starting to receive anti-TNF therapy and 3522 biologic-naive patients receiving conventional DMARDs found no associated increased risk of mortality in patients receiving TNF inhibitors compared with patients receiving conventional DMARDs.
A 2011 systematic review and meta-analysis by Mariette and colleagues of 2039 full-text papers and 1979 abstracts from conferences found that TNF inhibitors do not appear to increase risk of malignancy, specifically lymphoma; however, TNF inhibitors were associated with an increased risk of melanoma.
Learn more about side effects and risks associated with pharmacologic therapy for RA.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Herbert S. Diamond. Fast Five Quiz: Rheumatoid Arthritis Management - Medscape - Jun 10, 2020.